Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB])

被引：6
|
作者：
Phillips, Heidi
Sandmann, Thomas
Li, Congfen
Cloughesy, Timothy Francis
Chlnot, Olivier L.
Wick, Wolfgang
Nishikawa, Ryo
Mason, Warren P.
Henriksson, Roger
Saran, Frank
Lai, Albert
Moore, Nicola
Hegde, Priti S.
Abrey, Lauren E.
Bourgon, Richard
Garcia, Josep
Bais, Carlos
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Univ Aix Marseille, CHU Timone, AP HM, Serv Neurooncol, Marseille, France
[4] Heidelberg Univ, Neurooncol, Med Ctr, Heidelberg, Germany
[5] Saitama Med Univ, Saitama, Japan
[6] Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] Reg Canc Ctr Stockholm Gotland, Stockholm, Sweden
[8] Royal Marsden NHS Fdn Trust, Surrey, England
[9] UCLA Neurooncol Program, Los Angeles, CA USA
[10] F Hoffmann La Roche, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2001
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
    Chinot, Olivier L.
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Carpentier, Antoine F.
    Hoang-Xuan, Khe
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba A.
    Hilton, Magalie
    Abrey, Lauren
    Cloughesy, Timothy
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (08): : 709 - 722
  • [12] SAFETY RESULTS FROM AVAglio, A PHASE III RANDOMIZED STUDY OF BEVACIZUMAB (BEV) PLUS STANDARD COMBINATION TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Saran, Frank
    Chinot, Olivier L.
    Henriksson, Roger
    Mason, Warren
    Wick, Wolfgang
    Nishikawa, Ryo
    Dahr, Sunita
    Hilton, Magalie
    Garcia, Josep
    Cloughesy, Timothy
    [J]. NEURO-ONCOLOGY, 2013, 15 : 127 - 128
  • [13] Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
    Saran, Frank
    Welsh, Liam
    James, Allan
    McBain, Catherine
    Gattamaneni, Rao
    Jefferies, Sarah
    Harris, Fiona
    Cseh, Agnieszka
    Pemberton, Karine
    Schaible, Jennifer
    Bender, Shaun
    Brada, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [14] Bevacizumab in Combination With Radiotherapy and Temozolomide for PatientsWith Newly Diagnosed Glioblastoma Multiforme
    van Linde, Myra E.
    Verhoeff, Joost J. C.
    Richel, Dirk J.
    van Furth, Bwouter R.
    Reijneveld, Jaap C.
    Verheul, Henk M. W.
    Stalpers, Lukas J. A.
    [J]. ONCOLOGIST, 2015, 20 (02): : 107 - 108
  • [15] SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])
    Cloughesy, Tim
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Carpentier, Antoine F.
    Hoang-Xuan, Khe
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba A.
    Revil, Cedric
    Abrey, Lauren
    Chinot, Olivier L.
    [J]. NEURO-ONCOLOGY, 2014, 16
  • [16] Phase III Trial of Bevacizumab Added to Standard Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Final Progression-Free Survival and Preliminary Overall Survival Results from AVAglio
    Cloughsey, Timothy
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Hilton, Magalie
    Abrey, Lauren
    Chinot, Olivier
    [J]. NEUROLOGY, 2013, 80
  • [17] Phase III Trial of Bevacizumab Added to Standard Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Final Progression-Free Survival and Preliminary Overall Survival Results from AVAglio
    Cloughsey, Timothy
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Hilton, Magalie
    Abrey, Lauren
    Chinot, Olivier
    [J]. NEUROLOGY, 2013, 80
  • [18] PHASE III TRIAL OF BEVACIZUMAB ADDED TO STANDARD RADIOTHERAPY AND TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA: MATURE PROGRESSION-FREE SURVIVAL AND PRELIMINARY OVERALL SURVIVAL RESULTS IN AVAGLIO
    Chinot, Olivier
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Hilton, Magalie
    Abrey, Lauren
    Cloughesy, Timothy
    [J]. NEURO-ONCOLOGY, 2012, 14 : 101 - 101
  • [19] FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA
    Chinot, Olivier L.
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Carpentier, Antoine F.
    Khe Hoang-Xuan
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba A.
    Hilton, Magalie
    Kerloeguen, Yannick
    Guijarro, Abajo
    Cloughsey, Timothy
    [J]. NEURO-ONCOLOGY, 2013, 15 : 105 - 106
  • [20] Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
    Omuro, Antonio
    Beal, Kathryn
    Gutin, Philip
    Karimi, Sasan
    Correa, Denise D.
    Kaley, Thomas J.
    DeAngelis, Lisa M.
    Chan, Timothy A.
    Gavrilovic, Igor T.
    Nolan, Craig
    Hormigo, Adilia
    Lassman, Andrew B.
    Mellinghoff, Ingo
    Grommes, Christian
    Reiner, Anne S.
    Panageas, Katherine S.
    Baser, Raymond E.
    Tabar, Viviane
    Pentsova, Elena
    Sanchez, Juan
    Barradas-Panchal, Renata
    Zhang, Jianan
    Faivre, Geraldine
    Brennan, Cameron W.
    Abrey, Lauren E.
    Huse, Jason T.
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (19) : 5023 - 5031
12345